Business Context and Reporting Period
This Form 8-K was filed by MRI Interventions, Inc. (announcing a name change to ClearPoint Neuro, Inc.) on January 13, 2020, reporting events occurring on January 11, 2020. The filing primarily details a material definitive agreement for a financing transaction and references a press release regarding financial performance for the fourth fiscal quarter ended December 31, 2019.
Key Financial Metrics and Transaction Details
The filing discloses a financing transaction involving the issuance of floating rate secured convertible notes. Specific operational financial metrics (revenue, profit, cash flow) are not detailed in the text of this 8-K but are referenced in an attached press release (Exhibit 99.1).
- Initial Financing: $17,500,000 aggregate principal amount of "First Closing Notes."
- Investors: PTC Therapeutics, Inc. and Petrichor Opportunities Fund I LP.
- Additional Capacity: The company has the right to request up to $15,000,000 in additional notes ("Second" and "Third Closing Notes") from Petrichor by January 11, 2022.
- Interest Rate: LIBOR (3-month) or 2% (whichever is greater) plus a margin of 2% for the First Closing Notes and 7% for subsequent notes.
- Conversion Price: $6.00 per share of Common Stock.
- Maturity: Five years from the closing/issuance date.
- Security: The notes are secured obligations of the company.
Material Changes and Covenants
The entry into the Securities Purchase Agreement represents a significant change in the company's capital structure and debt obligations. The agreement imposes several restrictive covenants while the notes are outstanding:
- Restrictions on incurring additional indebtedness (except permitted indebtedness).
- Restrictions on permitting liens on properties.
- Prohibitions on making payments on junior securities, paying dividends, or transferring certain assets.
- Requirement to maintain a minimum amount of unrestricted cash.
- Requirement to seek shareholder approval by June 30, 2020, for the issuance of common stock upon conversion of the notes to comply with Nasdaq listing standards.
Outlook, Risks, and Unusual Items
Outlook and Conditions: The closing of the financing is subject to customary conditions, with an anticipated closing date prior to February 29, 2020. Failure to obtain shareholder approval for the stock issuance by June 30, 2020, will result in an increase to the interest rate of the notes.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to market conditions and the satisfaction of closing conditions. There is no assurance the transaction will close on the described terms or in a timely manner.
Unusual Items: The company announced a corporate name change from MRI Interventions, Inc. to ClearPoint Neuro, Inc. via a press release dated January 13, 2020.
Investor Verification Checklist
- Verify the final closing date of the $17.5 million financing and whether the full amount was received.
- Review the attached press release (Exhibit 99.1) for specific Q4 2019 revenue, net loss, and cash burn figures not included in this summary.
- Confirm whether the company successfully obtained shareholder approval for the note conversion by the June 30, 2020 deadline to avoid interest rate penalties.
- Monitor the company's unrestricted cash balance to ensure compliance with the minimum cash covenant.
- Check for any subsequent filings regarding the exercise of the option to issue the additional $15 million in notes.